ferric derisomaltose · Pharmacosmos · NDA 208171
Monoferric
Earliest generic entry, as listed
22 Jun 2036
Blocked by patent: US 11633489. Only method-of-use patents remain, so a generic may carve out the protected indication and enter earlier.
Listed patents · 5 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 11633489 | use U-3594 | 22 Jun 2036 |
| US 8815301 | substance, product, use U-2734 | 14 Aug 2029 |
| US 10414831 | substance, product | 25 Mar 2029 |
| US 11851504 | substance, product | 25 Mar 2029 |
| US 12030962 | substance, product | 25 Mar 2029 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 3
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 208171 · 001 · RLD · discontinued | solution, intravenous | 100MG/ML (100MG/ML) | 22 Jun 2036 |
| 208171 · 002 · RLD · discontinued | solution, intravenous | 500MG/5ML (100MG/ML) | 22 Jun 2036 |
| 208171 · 003 · RLD | solution, intravenous | 1GM/10ML (100MG/ML) | 22 Jun 2036 |